Your Article Summary
See Latest ArticlesCochrane Musculoskeletal Group review: Acute gout
The Journal of Family Practice, 07/02/09
Winzenberg T et al. - Gout afflicts about 2% of men over age 30 and women over age 50 and its prevalence appears to be increasing. Options for treating acute gout include nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, and intra-articular and systemic corticosteroids. Choosing among them can be challenging, however, because the evidence that one or another of these options yields real benefit is of varying strength. Using NSAIDs can be problematic with increasing age, as comorbidities like gastrointestinal (GI) bleeding, renal failure, heart failure, and cardiovascular risk increase and anticoagulant therapy is more likely to be in use. That’s where the kind of systematic reviews Cochrane Musculoskeletal Group (CMSG) performs can be of real help.
- Test your skills with 2 cases
- All 22 participants who took colchicine developed diarrhea or vomiting within 24 hours of initiating therapy
- One RCT found that oral prednisolone 35 mg daily and naproxen 500 mg twice daily were clinically equivalent
- NSAIDs are a reasonable first option, provided there are no contraindications
Related Articles
Outcome Domains for Studies of Acute and Chronic Gout
Journal of Rheumatology, 10/20/09
Relevance Score: 69%
Progress in Measurement Instruments for Acute and Chronic Gout Studies
Journal of Rheumatology, 10/23/09
Relevance Score: 68%
The modern management of gout
Rheumatology, 10/08/09
Relevance Score: 66%
Acute chylous ascites mimicking acute appendicitis in a patient with pancreatitis
World Journal of Gastroenterology, 10/20/09
Relevance Score: 47%
Acute silent cerebral infarction in children with sickle cell anemia
Pediatric Blood & Cancer, 10/09/09
Relevance Score: 46%
Today in Gout and Hyperuricemia...keeping you current
Receive free subspecialty "5-minute updates" via email
Common Polymorphisms Influencing Serum Uric Acid Levels Contribute to Susceptibility to Gout, but Not to Coronary Artery Disease
PLoS ONE - Cardiovascular Disorders, 11/10/09
The modern management of gout
Rheumatology, 10/08/09
Hyperuricemia Is a Mediator of Endothelial Dysfunction and Inflammation in Renal Allograft Recipients
Transplantation Proceedings, 11/02/09